A new approach for neurological evaluation of infants in resource-poor settings

Annals of Tropical Paediatrics

Volumn 22, Issue 4, 2002, Pages 355-368

  Haataja, Leena ^a,e   McGready, Rose ^b,c,d   Arunjerdja, Ratree ^b   Simpson, Julie A ^c,d,f   Mercuri, Eugenio ^a   Nosten, François ^b,c,d   Dubowitz, Lilly ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^e TURKU UNIVERSITY HOSPITAL   (Finland)

^f UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG; TOXIN;

CHILD HEALTH;

ARTICLE; COHORT ANALYSIS; DEVELOPING COUNTRY; DISEASE COURSE; ETHNIC GROUP; HEALTH CARE PERSONNEL; HUMAN; INFANT; INFECTION; MEDICAL RESEARCH; MYANMAR; NERVOUS SYSTEM DEVELOPMENT; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; POVERTY; PRESCHOOL CHILD; REFUGEE; RURAL AREA; THAILAND; UNITED KINGDOM; VALIDATION PROCESS;

CHILD BEHAVIOR DISORDERS; CHILD DEVELOPMENT; CHILD, PRESCHOOL; COHORT STUDIES; DEVELOPING COUNTRIES; HUMANS; INFANT; INFANT BEHAVIOR; NEUROPSYCHOLOGICAL TESTS; PSYCHOMOTOR DISORDERS; REPRODUCIBILITY OF RESULTS; RURAL HEALTH; THAILAND;

EID: 0036941188     PISSN: 02724936     EISSN: None     Source Type: Journal    
DOI: 10.1179/027249302125002029     Document Type: Article

References (24)

1. Weinke T, Trautmann M, Held T, et al. Neuropsychiatric side effects after the use of mefloquine. Am J Trop Med Hyg 1991; 45:86-9.
2. Phillips-Howard PA, ter Kuile FO. CNS adverse events associated with antimalarial agents. Fact or fiction? Drug Safety 1995; 12:370-83.
3. Costello AM de L. Perinatal health in developing countries. Trans R Soc Trop Med Hyg 1993; 87:1-2.
4. Nosten F, ter Kuile F, Chongsuphajaisiddhi T, et al. Mefloquine-resistant falciparum malaria on the Thai-Burmese border. Lancet 1991; 337:1140-3.
5. ter Kuile FO, Luxemburger C, Nosten F, et al. Serious neuropsychiatric adverse events following mefloquine treatment: evidence for a dose relationship? University of Amsterdam, PhD Thesis, 1994; 173-82.
6. Nosten F, van Vugt M. Neuropsychiatric adverse effects of mefloquine: what do we know and what should we know? CNS Drugs 1999; 11:1-8.
7. Dubowitz L, Mercuri E, Dubowitz V. An optimality score for the neurologic examination of the term newborn. J Pediatr 1998; 133:406-16.
8. Griffiths R. The Abilities of Babies. Amersham, UK: Association for Research in Infant and Child Development, 1976.
9. Henderson SE, Sugden D. The Movement Assessment Battery for Children. London: Psychological Corporation, 1992.
10. Haataja L, Mercuri E, Regev R, et al. Optimality score for the neurologic examination of the infant at 12 and 18 months of age. J Pediatr 1999; 135:153-61.
11. Bayley N. Bayley Scales of Infant Development Manual, 2nd edn. San Antonio: The Psychological Corporation (BSID-II), 1993.
12. Illingworth RS. The Normal Child, 10th edn. Edinburgh: Churchill Livingstone, 1991.
13. Losoff B, Brittenham GM, Wolf AW, et al. Iron deficiency anaemia and iron therapy effects on infant developmental test performance. Pediatrics 1987; 79:981-95.
14. Losoff B, Jimenez E, Wolf AW. Long-term developmental outcome of infants with iron deficiency. N Engl J Med 1991; 325:687-94.
15. Qazi SA, Khan MA, Mughal N, et al. Dexamethasone and bacterial meningitis in Pakistan. Arch Dis Child 1996; 75:482-8.
16. Wasserman G, Graziano JH, Factor-Litvak P, et al. Independent effects of lead exposure and iron deficiency anaemia on developmental outcome at age 2 years. J Pediatr 1992; 121:695-703.
17. Wolf AW, Jimenez E, Lozoff B. No evidence of developmental ill effects of low-level lead exposure in a developing country. J Dev Behav Pediatr 1994; 15:224-31.
18. Wolf MJ, Wolf B, Bijleveld C, Beunen G, Casaer P. The predictive value of developmental testing of extremely jaundiced African infants. Dev Med Child Neurol 1998; 40:405-10.
19. Frankenburg WK. The Denver approach to early case finding. In: Frankenburg WK, Emde RN, Sullivan JW, eds. Early Identification of Children at Risk. New York, NY: Plenum Press, 1985; 135-58.
20. Frankenburg WK, Dodds J, Archer P, Shapiro H, Bresnick B. The Denver II: a major revision and restandardization of the Denver Developmental Screening Test. Pediatrics 1992; 89:91-7.
21. Meisels SJ. Can developmental screening tests identify children who are developmentally at risk? Pediatrics 1989; 83:578-85.
22. Akaragian S, Dewa C. Standardization of the Denver Developmental Screening test for Armenian children. J Pediatr Nurs 1992; 7:106-9.
23. Lim HC, Chan T, Yoong T. Standardisation and adaptation of the Denver Developmental Screening Test (DDST) and Denver II for use in Singapore children. Singapore Med J 1994; 35:156-60.
24. Brachlow A, Jordan AE, Tervo R. Developmental screenings in rural settings: a comparison of the child development review and the Denver II Developmental Screening Test. J Rural Health 2001; 17:156-9.